Inventiva (NASDAQ:IVA) Trading Down 5.5% – Here’s Why

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was down 5.5% during trading on Monday . The company traded as low as $3.80 and last traded at $3.7910. Approximately 32,659 shares changed hands during mid-day trading, a decline of 46% from the average daily volume of 60,018 shares. The stock had previously closed at $4.01.

Analysts Set New Price Targets

A number of research firms have weighed in on IVA. HC Wainwright lifted their price target on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Wall Street Zen raised shares of Inventiva to a “hold” rating in a report on Saturday, October 18th. Guggenheim increased their price target on shares of Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Wolfe Research upgraded shares of Inventiva to a “strong-buy” rating in a research note on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Inventiva currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.75.

Inventiva Price Performance

The stock has a 50 day moving average price of $5.35 and a two-hundred day moving average price of $4.19.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Inventiva stock. Wealth Enhancement Advisory Services LLC grew its stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) by 54.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,558 shares of the company’s stock after purchasing an additional 5,843 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Inventiva were worth $50,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.